Quantitative MR Imaging in Locally Advanced Cervical Cancer

• Register: ClinicalTrials.gov
• Last refreshed on: 12 December 2020
• Main ID: NCT03210428
• Date of registration: 03/07/2017
• Prospective Registration: Yes
• Primary sponsor: Aarhus University Hospital
• Public title: Quantitative MR Imaging in Locally Advanced Cervical Cancer IQ-EMBRACE
• Scientific title: Quantitative MR Imaging in Locally Advanced Cervical Cancer Sub-study Under the EMBRACE II Protocol
• Date of first enrolment: October 18, 2018
• Target sample size: 320
• Recruitment status: Recruiting
• URL: https://clinicaltrials.gov/show/NCT03210428
• Study type: Observational

Countries of recruitment

Denmark

Contacts

• Name: Jacob C. Lindegaard, M.D.

Key inclusion & exclusion criteria

Inclusion Criteria:

- Patients included in the EMBRACE study (see inclusion criteria in the EMBRACE
protocol)

- Patients without previous record of allergic reaction to infusion of protocol related
contrast media (Gadolinium-based)

- Patients with sufficient kidney function according to local regulations

- Patient informed consent

Exclusion Criteria:

- According to EMBRACE II protocol

- Patients with active infection or severe medical condition



Age minimum: 18 Years
Age maximum: N/A
Gender: Female

Health Condition(s) or Problem(s) studied

Functional Magnetic Resonance Imaging

Neoplasms

Radiotherapy

Primary Outcome(s)

Disease control measure [Time Frame: 5 years]

Secondary Outcome(s)

Radiomics [Time Frame: 5 years]

Secondary ID(s)

57480

Source(s) of Monetary Support

Please refer to primary and secondary sponsors

Secondary Sponsor(s)

The Netherlands Cancer Institute